美国食品药品监督管理局（FDA）已正式批准施贵宝公司研发的Sotyktu®（通用名：Deucravacitinib）用于治疗成人活动性银屑病关节炎。这一决定为患者提供了一种全新的口服治疗选择，有望显著改善其生活质量。
美国食品药品监督管理局（FDA）已正式批准施贵宝公司研发的Sotyktu®（通用名：Deucravacitinib）用于治疗成人活动性银屑病关节炎。这一决定为患者提供了一种全新的口服治疗选择，有望显著改善其生活质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.